Skip to main content Back to Top


Disulfiram Tablets

Products Affected - Description

    • Antabuse tablet, Teva, 250 mg, bottle, 100 count, NDC 00093-5035-01
    • Antabuse tablet, Teva, 500 mg, bottle, 100 count, NDC 00093-5036-01
    • Disulfiram tablet, Alvogen, 250 mg, bottle, 30 count, NDC 47781-0607-30

Reason for the Shortage

    • Alvogen has the product on shortage due to shipping delays.
    • TEVA did not provide a reason for the shortage.
    • Mylan discontinued disulfiram tablets.
    • Rising Pharmaceuticals discontinued disulfiram tablets.

Available Products

    • There are no presentations available

Estimated Resupply Dates

    • Alvogen has disulfiram 250 mg tablets on back order and the company cannot estimate a release date.
    • Teva has disulfiram 250 mg and 500 mg tablets on back order and the company cannot estimate a release date.


Updated November 21, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. Created October 1, 2019 by Rachael Freeman, PharmD, BCPS. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.


This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins